CEO Brian Lian highlighted the company's progress in advancing its VK2735 obesity program, with Phase 3 trials for the subcutaneous formulation set to begin later in Q2 2025. Additionally, enrollment ...
The MarketWatch News Department was not involved in the creation of this content. VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN ...
Lian said the company expects to announce Phase II oral VK2735 results later in the year and is planning to evaluate a monthly dosing regimen for VK2735 in the maintenance setting later this year. The ...
Anthony Alfredo will drive the No. 96 Chevrolet, a second entry for Viking Motorsports, in the NASCAR O'Reilly Auto Parts ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback